

Nabriva Therapeutics Receives ZIT Grant for Extended Spectrum Pleuromutilin (ESP) Program

Vienna, Austria, January 27, 2014 – Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for serious infections caused by resistant pathogens, announced the receipt of an R&D grant from the ZIT (Technology Agency of the City of Vienna). In the course of the ZIT call “From Science to Products 2013” Nabriva received funds for its in-house Extended Spectrum Pleuromutilins program (ESP). ESP extend the conventional spectrum of known pleuromutilins by important Gram-negative bacteria, addressing a significant unmet medical need.

The ZIT grant supports the optimization of novel ESP candidates so that they can be administered by both intravenous and oral route allowing significant reduction in overall treatment costs.

“This grant is a substantial contribution to the further development of our pipeline. It shows that our ESP program has been recognized for its strong potential to develop a new class of antibacterials that addresses the need for new treatment options in an area facing growing resistance against all established antibiotics.”, stated Ralf Schmid, Nabriva’s CEO.

For further information about ZIT, please visit: <http://www.zit.co.at/>

About Nabriva Therapeutics

Nabriva Therapeutics AG is a biotechnology company focused on developing a new class of antibiotics, pleuromutilins, for the treatment of serious infections caused by resistant pathogens and sexually transmitted diseases. The company’s lead product BC-3781 is a broad spectrum agent, tested in over 400 people in both oral and i.v. administrations. Proof of concept for the systemic use of BC-3781 in humans was achieved in a Phase 2 trial in patients with acute bacterial skin and skin structure infections (ABSSSI) as well as community-acquired bacterial pneumonia (CABP) addressing a global multi billion dollar market. Phase 3 preparations are currently underway.

BC-7013, a topical treatment, has completed Phase 1 trials in dermatological diseases. In preclinical studies, the company is developing extended spectrum pleuromutilins (ESPs) with broad activity against both Gram-positive and Gram-negative bacterial infections. The company is backed by leading international investors: Phase4 Partners, HBM Partners, Wellcome Trust, Global Life Science Ventures and the Novartis Venture Fund. Nabriva currently employs 35 employees at its headquarter in Vienna, Austria.

For more information on Nabriva please visit www.nabriva.com.

Contact us

NABRIVA THERAPEUTICS AG
Ralf Schmid
Chief Executive Officer
T +43 (0)1 740 930
office@nabriva.com

For press inquiries: MC SERVICES AG
Raimund Gabriel
Managing Partner
T +49 89 210 228-30
Raimund.gabriel@mc-services.eu